- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - mnc pharma
- SANOFI INDIA - ADCOCK INGRAM (S. Africa)
SANOFI INDIA vs ADCOCK INGRAM (S. Africa) - Comparison Results
SANOFI INDIA 
Change
Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 SANOFI INDIA  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SANOFI INDIA Dec-17 |
ADCOCK INGRAM Jun-14 |
SANOFI INDIA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 4,945 | 368 | - | |
| Low | Rs | 3,901 | 265 | - | |
| Sales per share (Unadj.) | Rs | 1,081.8 | 109.3 | - | |
| Earnings per share (Unadj.) | Rs | 141.6 | -27.6 | - | |
| Cash flow per share (Unadj.) | Rs | 185.9 | -22.8 | - | |
| Dividends per share (Unadj.) | Rs | 33.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.7 | 0 | - | |
| Book value per share (Unadj.) | Rs | 868.8 | 85.8 | - | |
| Shares outstanding (eoy) | m | 23.03 | 168.78 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.1 | 2.9 | 141.3% | |
| Avg P/E ratio | x | 31.2 | -11.5 | -272.1% | |
| P/CF ratio (eoy) | x | 23.8 | -13.9 | -171.7% | |
| Price / Book Value ratio | x | 5.1 | 3.7 | 138.1% | |
| Dividend payout | % | 23.3 | 0 | - | |
| Avg Mkt Cap | Rs m | 101,862 | 53,397 | 190.8% | |
| No. of employees | `000 | 3.2 | 4.3 | 75.4% | |
| Total wages/salary | Rs m | 3,685 | 3,351 | 110.0% | |
| Avg. sales/employee | Rs Th | 7,691.9 | 4,298.8 | 178.9% | |
| Avg. wages/employee | Rs Th | 1,137.7 | 780.6 | 145.7% | |
| Avg. net profit/employee | Rs Th | 1,006.5 | -1,083.2 | -92.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 24,914 | 18,455 | 135.0% | |
| Other income | Rs m | 807 | 129 | 624.4% | |
| Total revenues | Rs m | 25,721 | 18,584 | 138.4% | |
| Gross profit | Rs m | 5,372 | -3,198 | -168.0% | |
| Depreciation | Rs m | 1,022 | 796 | 128.3% | |
| Interest | Rs m | 11 | 500 | 2.2% | |
| Profit before tax | Rs m | 5,146 | -4,365 | -117.9% | |
| Minority Interest | Rs m | 0 | -12 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,886 | 273 | 691.4% | |
| Profit after tax | Rs m | 3,260 | -4,650 | -70.1% | |
| Gross profit margin | % | 21.6 | -17.3 | -124.4% | |
| Effective tax rate | % | 36.6 | -6.2 | -586.5% | |
| Net profit margin | % | 13.1 | -25.2 | -51.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 14,432 | 13,517 | 106.8% | |
| Current liabilities | Rs m | 6,010 | 7,605 | 79.0% | |
| Net working cap to sales | % | 33.8 | 32.0 | 105.5% | |
| Current ratio | x | 2.4 | 1.8 | 135.1% | |
| Inventory Days | Days | 61 | 111 | 54.9% | |
| Debtors Days | Days | 28 | 124 | 23.0% | |
| Net fixed assets | Rs m | 7,991 | 7,879 | 101.4% | |
| Share capital | Rs m | 230 | 86 | 268.8% | |
| Net worth | Rs m | 20,008 | 14,485 | 138.1% | |
| Long term debt | Rs m | 0 | 5,090 | 0.0% | |
| Total assets | Rs m | 27,770 | 27,363 | 101.5% | |
| Interest coverage | x | 468.8 | -7.7 | -6,063.2% | |
| Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
| Sales to assets ratio | x | 0.9 | 0.7 | 133.0% | |
| Return on assets | % | 11.8 | -15.2 | -77.7% | |
| Return on equity | % | 16.3 | -32.1 | -50.8% | |
| Return on capital | % | 25.8 | -19.8 | -130.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 4,351 | 1,575 | 276.2% | |
| From Investments | Rs m | -787 | -484 | 162.7% | |
| From Financial Activity | Rs m | -1,884 | 4,620 | -40.8% | |
| Net Cashflow | Rs m | 1,680 | 5,711 | 29.4% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.07 Rs / ZAR
Compare SANOFI INDIA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare SANOFI INDIA With: CIPLA AJANTA PHARMA SUVEN LIFE AUROBINDO PHARMA FDC LTD.
|
| |
Today's Market
Sensex Ends 142 Points Higher; Metal and Healthcare Stocks Witness Buying(Closing)
Indian share markets continued their momentum during closing hours and ended the day on a positive note. Gains were largely seen in the metal sector and healthcare sector.
Related Views On News
SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)
Nov 6, 2018 | Updated on Nov 6, 2018For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)
Jul 27, 2018 | Updated on Jul 27, 2018For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)
Feb 13, 2019The real estate sector is ready to make a comeback. This is the stock to consider buying.
Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)
Feb 14, 2019During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)
Feb 8, 2019This is the trick to following super investors and not losing money.
Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)
Feb 14, 2019Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)
Feb 15, 2019Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.
More|
| |
SANOFI INDIA SHARE PRICE
Feb 21, 2019 03:35 PM
TRACK SANOFI INDIA
- Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SANOFI INDIA
SANOFI INDIA 8-QTR ANALYSIS
COMPARE SANOFI INDIA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.